Results 151 to 160 of about 26,258 (175)

Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy. [PDF]

ESC Heart Fail
Usai P, Cariou E, Donal E, Eyharts D, Cohen N, Lucas C, Al Wazzan A, Cherbi M, Itier R, Fournier P, Habib G, Lairez O.   +11 more
europepmc   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]

Int J Mol Sci
Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, Yano T, Inomata T.   +7 more
europepmc   +1 more source

Spatial control of myosin regulatory light chain phosphorylation modulates cardiac thick filament mechanosensing. [PDF]

Proc Natl Acad Sci U S A
Squarci C, Koch D, Anaya P, Campbell KS, Kampourakis T.   +4 more
europepmc   +1 more source

Mavacamten Reduces LVOT Obstruction Risk, Enabling Transseptal Mitral Valve-in-Valve for Degenerated Bioprosthesis. [PDF]

JACC Case Rep
Hoss A, Voß F, Polzin A.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis

Cell Reports, 2022
Taejoon Won, Mónica V Talor, Ninaad Lasrado   +2 more
exaly  

FDA approves first cardiac myosin inhibitor

Nature Reviews Drug Discovery, 2022
Mullard Asher
exaly